Preview

Cancer Urology

Advanced search

Characteristics of tissue expression of extracellular matrix proteolytic enzymes and their inhibitors in patients with bladder cancer

https://doi.org/10.17650/1726-9776-2017-13-2-96-103

Abstract

Objectives. Levels and expression of matrix metalloproteases 2 (MMP-2), MMP-9, MMP-14 and tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2 were studied by immunohistochemistry in tumor and surrounding tissues in 73 patients with superficial bladder cancer (BC) ТаN0M0 and Т1N0M0 depending on the disease characteristics.

 Results. The study showed the initial increase in the number of tumor cells expressing MMP-2, MMP-9 and MMP-14 and their tissue inhibitors, compared to histologically unchanged tissues and tumor-adjacent tissues. The number of MMP-9 producing tumor cells was maximal. Tissue expression of TIMP-1 and TIMP-2 in tumor cells in superficial BC patients was higher than in unchanged tissues and in tumor-adjacent tissues. The ratio of MMP and TIMP expression differed, and the proteolytic potential of MMP was higher than that of TIMP.

Conclusion. The study demonstrated the influence of the primary bladder cancer stage (from Ta to T1), tumor differentiation grade (from G1 to G2) and prognosis of the disease course (from favorable to intermediate) on the enhancing expression of MMP-9 and TIMP-1 in tumor tissues in superficial BC. 

About the Authors

A. N. Shevchenko
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation


O. I. Kit
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation


E. F. Komarova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation


E. A. Nikipelova
Rostov Research Institute of Oncology, Ministry of Health of Russia


A. A. Demidova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation


D. I. Pakus
Clinical and Diagnostics Center “Health
Russian Federation
70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011


V. A. Sergan
AMEOS Seepark Hospital Geestland Clinic for Urology and Pediatric Urology
Germany


E. V. Filatova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation
63 14th Liniya St., Rostov-on-Don 344037


I. A. Khomutenko
Rostov Research Institute of Oncology, Ministry of Health of Russia
Russian Federation


References

1. Рогова Л.Н., Шестернина Н.В., Замечник Т.В. и др. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах (обзор). Вестник новых медицинских технологий 2011;8(2):86–9. [Rogova L.N., Shesternina N.V., Zamechnik T.V. et al. Matrix metalloproteinases and their role in physiological and pathological processes (review). Vestnik novykh meditsinskikh tekhnologiy = Journal of New Medical Technologies 2011;8(2):86–9. (In Russ.)]

2. Кит О.И., Франциянц Е.М., Никипелова Е.А. и др. Изменения маркеров пролиферации, неоангиогенеза и системы активации плазминогена в ткани рака прямой кишки. Экспериментальная и клиническая гастроэнтерология 2015;2(114):40–5. [Kit O.I., Frantsiyants E.M., Nikipelova E.A. et al. Changes in markers of proliferation, neoangiogenesis and plasminogen activation system in rectal cancer tissue. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2015;2(114):40–5. (In Russ.)].

3. Аль-Шукри А.С., Данильченко Д.И. Диагностическая и прогностическая ценность определения матрикс-металлопротеаз в моче у больных раком мочевого пузыря. Нефрология 2009;13(1):87–9. [Al’-Shukri A.S., Danil’chenko D.I. The diagnostic and prognostic value of the determination of matrix-metalloproteinases in the urine of patients with urinary bladder cancer. Nefrologiya = Nephrology 2009;13(1): 87–9. (In Russ.)].

4. Кондакова И.В., Клишо Е.В., Савенкова О.В. и др. Содержание матриксных металлопротеиназ и их тканевых ингибиторов в сыворотке крови и опухолях при их метастазировании. Вестник национальной Академии наук Белоруссии 2008;(2):88–92. [Kondakova I.V., Klisho E.V., Savenkova O.V. et al. Serum and tumor levels of matrix metalloproteinases and their tissue inhibitors in metastasis. Vestnik natsionalnoy Аkademii nauk Belorussii = Proceeding of the National Academy of Sciences of Belarus 2008;(2):88–92. (In Russ.)].

5. Шевченко А.Н., Пакус Д.И., Комарова Е.Ф. и др. Некоторые показатели внеклеточного протеолиза в моче больных раком мочевого пузыря. Современные проблемы науки и образования 2016;(4). Доступно по: http://scienceeducation.ru/ru/article/view?id=25031. [Shevchenko A.N., Pakus D.I., Komarova E.F. et al. Some indicators of extracellular proteolysis in the urine of bladder cancer patients. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education 2016;(4). Available at: http://science-education.ru/ru/article/view?id=25031. (In Russ.)].

6. Завалишина Л.Э., Франк Г.А., Андреева Ю.Ю. Матриксные металлопротеиназы и их тканевые ингибиторы при уротелиальном раке мочевого пузыря и светлоклеточном раке почки. Материалы съезда онкологов СНГ, Баку, 26–28 сентября, 2006. С. 3. [Zavalishina L.E., Frank G.A., Andreeva Yu.Yu. Matrix metalloproteinases and their inhibitors in urothelial bladder cancer and clear cell renal cell carcinoma. Proceedings of the Congress of CIS Oncologists, Baku, September 26–28, 2006. P. 3. (In Russ.)].

7. Андреева Ю.Ю. Морфологические и молекулярно-биологические факторы прогноза рака мочевого пузыря. Автореф. дис. … д-ра мед. наук. М., 2009. [Andreeva Yu.Yu. Morphological and biomolecular factors in bladder cancer prognosis. Author’s abstract of thesis … of doctor of medical sciences. Moscow, 2009. (In Russ.)].

8. Van Steenkiste M., Oltenfreiter R., Frankenne F. et al. Membrane type 1 matrix metalloproteinase detection in tumors, using the lodinated endogenous tissue inhibitor 2 of metalloproteinases as imaging agent. Cancer Biother Radiopharm 2010;25(5):511–20. DOI: 10.1089/cbr.2010.0789. PMID: 20854210.

9. Wallard M.J., Pennington C.J., Veerakumarasivam A. et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer 2006;94(4):569–77. DOI: 10.1038/sj.bjc.6602931. PMID: 16465195.

10. Reis S.T., Leite K.R., Piovesan L.F. et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol 2012;12:18. DOI: 10.1186/1471-2490-12-18. PMID: 22695075.

11. Камоева С.В. Ранняя диагностика развивающегося пролапса тазовых органов у женщин репродуктивного возраста при отсутствии клинических признаков. Лечение и профилактика 2013;2(6):88–93. [Kamoeva S.V. The early diagnostic of developing prolapse of pelvic organs in women of reproductive age under absence of clinical signs. Lechenie i profilaktika = Disease Treatment and Prevention 2013;2(6):88–93. (In Russ.)].

12. Франк Г.А., Завалишина Л.Э., Андреева Ю.Ю. Уточняющая диагностика рака с использованием иммуногистохимического определения маркеров. Медицинская технология. М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий», 2009. [Frank G.A., Zavalishina L.E., Andreeva Yu.Yu. Specifying cancer diagnosis using immunohistochemical marker determination. Medical technology. Moscow: FGU “MNIOI im. P.A. Gertzena Rosmedtekhnologiy”, 2009. (In Russ.)].


Review

For citations:


Shevchenko A.N., Kit O.I., Komarova E.F., Nikipelova E.A., Demidova A.A., Pakus D.I., Sergan V.A., Filatova E.V., Khomutenko I.A. Characteristics of tissue expression of extracellular matrix proteolytic enzymes and their inhibitors in patients with bladder cancer. Cancer Urology. 2017;13(2):96-103. https://doi.org/10.17650/1726-9776-2017-13-2-96-103

Views: 1242


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X